Novartis
NVS
NVS
1,118 hedge funds and large institutions have $19.7B invested in Novartis in 2020 Q3 according to their latest regulatory filings, with 77 funds opening new positions, 346 increasing their positions, 458 reducing their positions, and 73 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
5% less capital invested
Capital invested by funds: $20.7B → $19.7B (-$1.08B)
13% less funds holding in top 10
Funds holding in top 10: 15 → 13 (-2)
24% less repeat investments, than reductions
Existing positions increased: 346 | Existing positions reduced: 458
Holders
1,118
Holding in Top 10
13
Calls
$178M
Puts
$125M
Top Buyers
1 | +$212M | |
2 | +$69.1M | |
3 | +$49.6M | |
4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$31.2M |
5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$29.6M |
Top Sellers
1 | -$314M | |
2 | -$171M | |
3 | -$140M | |
4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$119M |
5 |
FAM
Fred Alger Management
New York
|
-$108M |